The latest paper from lab, titled “Lysyl oxidase inhibition disrupts mitochondrial homeostasis to create vulnerability to ferroptosis in TNBC”, made the news within the first week of publication! You can read some of these news articles and learn more about our impactful research: A ‘one-two punch’ against aggressive breast cancer Aggressive Breast Cancer Has a New Weakness, Study Finds A ‘one-two punch’ against aggressive breast cancer
Our latest study, published in Cell Reports Medicine, uncovers an unexpected intracellular role for lysyl oxidase (LOX), traditionally known as an extracellular matrix regulator, in maintaining mitochondrial homeostasis and protecting triple-negative breast cancer (TNBC) cells from ferroptosis. Pharmacological inhibition of LOX with our best-in-class inhibitor, LXG6403, disrupts mitochondrial homeostasis and weakens ferroptosis defense mechanisms. As the cancer cells adapt, they become increasingly dependent on the backup DHODH pathway, creating a vulnerability that can be targeted with Read more
Our PI, Dr. Ozgur Sahin, has accepted the position of Program Director of Science Translation for the Hollings Advisory for Rapid Translation (HART). In this newly created role, he will lead and support strategic initiatives to advance the translation of basic science into investigator-initiated clinical research. We sincerely congratulate him on this achievement!
